Former UFC heavyweight champion has been notified by the US Anti-Doping Agency of a failed out-of-competition medication exam on 28 June
Brock Lesnar has been pennant for a potential anti-doping irreverence in the wake of his unanimous-decision win over Mark Hunt at UFC 200.
The UFC problem a declaration on Friday afternoon saying Lesnar and the advertisement had been notified by the US Anti-Doping Agency of a failed out-of-competition stimulant exam on 28 June. Usada did not discover the name of the substance Lesnar tested positive for in keeping with managerial policy.
A embellished amateur wrestler, Lesnar signed with the UFC in 2007 and thwarted Randy Couture for the advertisements heavyweight championship the following year. He attained two successful entitlement justifications before losing to Cain Velasquez by first-round TKO, then announced his retirement from motley martial arts after a stoppage loss to Alistair Overeem in 2011.
Saturdays fight with Hunt was Lesnars first in five years. The 38 -year-old South Dakota native deserved a record $2.5 m pocketbook for the three-round points acquire, with all three judges siding down tallies of 29 -2 8.
The UFC said Usada, the independent head of the organisation anti-doping policy, received the testing results from the 28 June sample collecting on Thursday evening after it was researched at the Wada-accredited UCLA Olympic Analytical Laboratory.
The original headline bout of Saturdays card a light heavyweight designation push between Jon Jones and Daniel Cormier was scrapped when Jones tested positive for a banned element. Cormier instead contended Anderson Silva on the undercard, while the status of women bantamweight championship oppose between Amanda Nunes and Miesha Tate was promoted to the main event.
The UFC 200 main event had to be scrapped three days before the event because Jon Jones tested positive for censored essences in an out-of-competition research. Daniel Cormier opposed Anderson Silva instead. Jones is also awaiting the USADA adjudication process.
Read more: www.theguardian.com